Anticoagulation-related nephropathy

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 3, 2016, Pages 461-467

  Wheeler, D S ^a   Giugliano, R P ^b   Rangaswami, J ^a,c  

^a EINSTEIN MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Delaware Valley Nephrology and Hypertension Associates   (United States)

Author keywords

Acute renal injury; Anticoagulants; International normalized ratio; Thrombin; Warfarin

Indexed keywords

ACTIVATED PROTEIN C; APIXABAN; CYTOCHROME P450 2C9; EDOXABAN; ENDOTHELIAL PROTEIN C RECEPTOR; HEMOSIDERIN; RIVAROXABAN; THROMBIN; WARFARIN; ANTICOAGULANT AGENT;

ACUTE KIDNEY FAILURE; ANTICOAGULATION RELATED NEPHROPATHY; DISEASE COURSE; ELECTROLYTE URINE LEVEL; EVIDENCE BASED PRACTICE; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; KIDNEY FUNCTION; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENOGRAPHY; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SURVIVAL RATE; TREATMENT INDICATION; URINALYSIS; ACUTE KIDNEY INJURY; ANIMAL; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; KIDNEY; METABOLISM; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

ACUTE KIDNEY INJURY; ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; GLOMERULAR FILTRATION RATE; HUMANS; INTERNATIONAL NORMALIZED RATIO; KIDNEY; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84960101427     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13229     Document Type: Review

References (29)

1. Brodsky SV, Nadasdy T, Rovin BH, Satoskar AA, Nadasdy GM, Wu HM, Bhatt UY, Hebert LA. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80: 181-9.
2. Brodsky SV, Satoskar A, Chen J, Nadasdy G, Eagen JW, Hamirani M, Hebert L, Calomeni E, Nadasdy T. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis 2009; 54: 1121-6.
3. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-106.
4. Reilly EB, Perry A, Fujita K, Nakamura RM. Haematuria and anticoagulants. Lancet 1964; 1: 554-6.
5. Brodsky SV, Collins M, Park E, Rovin BH, Satoskar AA, Nadasdy G, Wu H, Bhatt U, Nadasdy T, Hebert LA. Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract 2010; 115: c142-6.
6. An JN, Ahn SY, Yoon CH, Youn TJ, Han MK, Kim S, Chin HJ, Na KY, Chae DW. The occurrence of warfarin-related nephropathy and effects on renal and patient outcomes in Korean patients. PLoS One 2013; 8: e57661.
7. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-64.
8. Ryan M, Ware K, Qamri Z, Satoskar A, Wu H, Nadasdy G, Rovin B, Hebert L, Nadasdy T, Brodsky SV. Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. Nephrol Dial Transplant 2013; 29: 2228-34.
9. Ware KM, Vance JC, Muni N, Hebert LA, Satoskar AA, Nadasdy G, Ivanov I, Nadasdy T, Rovin BH, Brodsky SV. Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants? Am J Hypertens 2014; 28: 182-9.
10. Malik AB, Fenton JW 2nd. Thrombin-mediated increase in vascular endothelial permeability. Semin Thromb Hemost 1992; 18: 193-9.
11. Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC. Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol 2004; 24: 41-53.
12. Darrow AL, Fung-Leung WP, Ye RD, Santulli RJ, Cheung WM, Derian CK, Burns CL, Damiano BP, Zhou L, Keenan CM, Peterson PA, Andrade-Gordon P. Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost 1996; 76: 860-6.
13. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-13.
14. Christiaans SC, Wagener BM, Esmon CT, Pittet JF. Protein C and acute inflammation: a clinical and biological perspective. Am J Physiol Lung Cell Mol Physiol 2013; 305: L455-66.
15. Madhusudhan T, Wang H, Straub BK, Grone E, Zhou Q, Shahzad K, Muller-Krebs S, Schwenger V, Gerlitz B, Grinnell BW, Griffin JH, Reiser J, Grone HJ, Esmon CT, Nawroth PP, Isermann B. Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood 2012; 119: 874-83.
16. Venkatachalam MA, Griffin KA, Lan R, Geng H, Saikumar P, Bidani AK. Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol 2010; 298: F1078-94.
17. Pichette V, Leblond FA. Drug metabolism in chronic renal failure. Curr Drug Metab 2003; 4: 91-103.
18. Dreisbach AW, Japa S, Gebrekal AB, Mowry SE, Lertora JJ, Kamath BL, Rettie AE. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther 2003; 73: 475-7.
19. Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, Acton RT, Allon M. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20: 912-21.
20. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159: 340-7e1
21. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
22. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-104.
23. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
24. Moeckel GW, Luciano RL, Brewster UC. Warfarin-related nephropathy in a patient with mild IgA nephropathy on dabigatran and aspirin. Clin Kidney J 2013; 6: 507-9.
25. Bohm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY Trial. J Am Coll Cardiol 2015; 65: 2481-93.
26. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-51.
27. FDA Briefing Information for the September 8, 2011 Meeting of the Cardiovascular and Renal Drugs Advisory Committee, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM270796.pdf. Accessed 11 June 2015.
28. FDA Briefing Information, Dabigatran Etexilate Mesylate Capsules, for the September 20, 2010 Meeting of the Cardiovascular and Renal Drugs Advisory Committee, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM247244.pdf. Accessed 11 June 2015.
29. FDA Briefing Information for the October 30, 2014 Meeting of the Cardiovascular and Renal Drugs Advisory Committee, 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM420704.pdf. Accessed 11 June 2015.